Maxim downgraded Theriva Biologics (TOVX) to Hold from Buy with no price target The firm cites the company having announced top-line data from the Phase 2b VIRAGE study evaluating oncolytic virus candidate VCN-01 in combination with chemotherapy vs. chemotherapy alone in 1st line pancreatic cancer, noting that while the key measure of median overall survival demonstrated a 2.2 month improvement and a p value of 0.0546 was just over the threshold for statistical significance, in pancreatic cancer, the mOS is key and came in narrower than expected based on the prior data. Maxim calls the overall data “mixed and unimpressive”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics prices 6.8M shares at $1.10 in public offering
- Theriva Biologics announces primary endpoints for efficacy met in VIRAGE study
- Theriva Biologics Announces Positive VIRAGE Phase 2b Results
- Theriva Biologics Reports Positive VIRAGE Phase 2b Results
- Theriva Biologics says IDMC considers VCN-01 to be well tolerated